肺がん治療市場：分子、疾患、がん種、治療法、流通別-2025-2030年の世界予測

肺がん治療市場は、2023年に250億4,000万米ドルと評価され、2024年には271億2,000万米ドルに達すると予測され、CAGR 8.39％で成長し、2030年には440億3,000万米ドルに達すると予測されています。

肺がん治療の対象範囲には、化学療法、免疫療法、標的療法、放射線療法など、肺がんを治療・管理するための幅広い治療法が含まれます。これらの治療法の必要性は、肺がんが世界の負担となっていることに起因しており、肺がんは依然として世界のがん関連死亡の主要原因の1つです。用途は多岐にわたり、特定の遺伝子変異を標的とした治療レジメン、術前の腫瘍縮小支援、術後の回復促進などが含まれます。最終用途の範囲には、主に病院、腫瘍センター、学術・研究機関が含まれます。市場成長は、個別化治療計画につながる精密医療の進歩と腫瘍ゲノミクスへの理解の高まりに大きく影響されています。最新の潜在的なビジネスチャンスは、新薬や併用療法の承認率が高まり、副作用の少ないより効果的な治療へのシフトが期待されることから生まれています。さらに、製薬企業と研究機関の協力は、医薬品開発と市場参入を加速する上で極めて重要です。しかし、治療費の高騰、承認プロセスの長期化、地域間の治療アクセスの格差といった制約が大きな課題となっています。臨床試験の複雑さ、患者募集、規制上の課題も市場成長の妨げとなります。現在、革新のための最良の分野は、患者と適切な治療法をより適切にマッチングさせるためのリキッドバイオプシーとコンパニオン診断の開発、および遺伝子・分子研究による新規ターゲットの探索にあります。市場はダイナミックで競争が激しく、急速な技術進歩を特徴としており、継続的な研究開発投資と戦略的パートナーシップの必要性を示しています。この複雑な情勢を乗り切るための効果的な戦略には、イノベーションの促進、価格戦略による患者アクセスの最大化、科学や規制状況の進展に迅速に適応するための機敏性の維持などがあります。

市場力学：急速に進化する肺がん治療市場の主要市場インサイトを公開

肺がん治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の肺がん罹患率の増加
  • 健康管理の強化に関する意識の高まり
  • 肺がん治療に対する政府のイニシアチブの高まり
• 市場抑制要因
  • ジェネリック医薬品の大量供給
  • 肺がん治療を受ける患者の平均余命の低下
• 市場機会
  • 新たな治療法の研究開発分野における資金提供の増加
  • 免疫療法などの先進治療の採用
• 市場の課題
  • 放射線療法や化学療法による副作用のリスク

ポーターの5つの力：肺がん治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：肺がん治療市場における外部からの影響の把握

外部マクロ環境要因は、肺がん治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析肺がん治療市場における競合情勢の把握

肺がん治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス肺がん治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、肺がん治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨肺がん治療市場における成功への道筋を描く

肺がん治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で肺がんの罹患率が増加
    • 強化された医療に関する意識の高まり
    • 肺がん治療に対する政府の取り組みの強化
  • 抑制要因
    • ジェネリック医薬品の豊富な供給
    • 肺がん治療を受ける患者の平均余命が短縮
  • 機会
    • 新しい治療の研究開発分野への資金提供の増加
    • 免疫療法などの先進治療の導入
  • 課題
    • 放射線治療と化学療法の副作用のリスク
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 肺がん治療市場分子別

• 生物学的製剤
• 小分子

第7章 肺がん治療市場：疾患別

• 非小細胞肺がん
• SCLC

第8章 肺がん治療市場がんの種類別

• 肺カルチノイド腫瘍
• 非小細胞肺がん
• 小細胞肺がん

第9章 肺がん治療市場セラピー

• 化学療法
• 免疫療法
  • アテゾリズマブ
  • デュルバルマブ
  • ニボルマブ
  • ペムブロリズマブ
• 放射線治療
  • 外部ビーム
  • 内部ビーム
  • 全身的
• 標的療法
  • ベバシズマブ
  • ダブラフェニブ/トラメチニブ
  • エルロチニブ塩酸塩
  • オシメルチニブ

第10章 肺がん治療市場配布元

• 病院薬局
• オンライン薬局
• 小売薬局

第11章 南北アメリカの肺がん治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の肺がん治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの肺がん治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Boehringer Ingelheim GmbH
• Bristol Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Genentech, Inc.
• GlaxoSmithKline PLC
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.

LIST OF FIGURES

• FIGURE 1. LUNG CANCER THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. LUNG CANCER THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. LUNG CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. LUNG CANCER THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NSCLC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SCLC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LUNG CARCINOID TUMOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INTERNAL BEAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DABRAFENIB/TRAMETINIB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ERLOTINIB HYDROCHLORIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OSIMERTINIB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHRAMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 65. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 66. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 67. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 68. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 69. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 70. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 71. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 72. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 99. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 102. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 103. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 105. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 106. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 107. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 108. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 109. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 110. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 111. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 112. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 113. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 114. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 115. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 116. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 117. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 118. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 119. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 120. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 121. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 122. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 123. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 124. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 125. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 126. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 127. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 128. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 129. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 130. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 131. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 132. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 133. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 134. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 135. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 136. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 137. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 138. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 139. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 140. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 141. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 142. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 143. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 144. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 145. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 146. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 147. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 148. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 149. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 150. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 151. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 152. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 153. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 154. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 155. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 156. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 157. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 158. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 159. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 160. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 161. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 162. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 171. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 172. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 173. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 174. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 175. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 176. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 177. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 178. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 179. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 180. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 181. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 182. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 183. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 184. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 185. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 186. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 187. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 188. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 189. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 190. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 191. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 192. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 193. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 194. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 204. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 205. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 206. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 207. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 208. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 209. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 210. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 211. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 212. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 213. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 214. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 215. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 216. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 217. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 218. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 219. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 220. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 221. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 222. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 223. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 224. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 225. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 226. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 227. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 228. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 229. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 230. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 231. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 232. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 233. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 234. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 235. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 236. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 237. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 238. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 239. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 240. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 241. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 242. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 243. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 244. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 245. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 246. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 247. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 248. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 249. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 250. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 251. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 252. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 253. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 254. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 255. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 256. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 257. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 258. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 259. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 260. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 261. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 262. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 263. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 264. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 265. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 266. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 267. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 268. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 269. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 270. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 271. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 272. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 273. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 274. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 275. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 276. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 277. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 278. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 279. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 280. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 281. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 282. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 283. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 284. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 285. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 286. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 287. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 288. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 289. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 290. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 291. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 292. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 293. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 294. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 295. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 296. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 297. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 298. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 299. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 300. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 301. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 302. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 303. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 304. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 305. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 306. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 307. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 308. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 309. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 310. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 311. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 312. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 313. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 314. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 315. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 316. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 317. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 318. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 319. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 320. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 321. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 322. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 323. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 324. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
• TABLE 325. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 326. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 327. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 328. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 329. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
• TABLE 330. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
• TABLE 331. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 332. SWEDEN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MI

The Lung Cancer Therapeutics Market was valued at USD 25.04 billion in 2023, expected to reach USD 27.12 billion in 2024, and is projected to grow at a CAGR of 8.39%, to USD 44.03 billion by 2030.

The scope of lung cancer therapeutics encompasses a broad range of interventions designed to treat and manage lung cancer, including chemotherapy, immunotherapy, targeted therapy, and radiation therapy. The necessity for these therapies is driven by the global burden of lung cancer, which remains one of the leading causes of cancer-related deaths worldwide. Applications are diverse, encompassing treatment regimens targeting specific genetic mutations, assisting in reducing tumor size pre-operatively, and enhancing post-operative recovery. End-use scope primarily includes hospitals, oncology centers, and academic and research institutions. Market growth is significantly influenced by advancements in precision medicine and a growing understanding of tumor genomics, leading to personalized treatment plans. Latest potential opportunities emerge from the increased approval rate of novel drugs and combinations, promising a shift towards more effective treatments with reduced side effects. Additionally, collaborations between pharmaceutical companies and research institutions are crucial to accelerating drug development and market entry. However, limitations such as high costs of therapy, prolonged approval processes, and the disparity in treatment accessibility across regions pose significant challenges. Complexities in clinical trials, patient recruitment, and regulatory challenges can also hinder market growth. The best areas for innovation currently lie in the development of liquid biopsies and companion diagnostics to better match patients with suitable therapies, as well as the exploration of new targets through genetic and molecular research. The market is dynamic, highly competitive, and characterized by rapid technological advancements, indicating a need for continuous R&D investment and strategic partnerships. Effective strategies to navigate this complex landscape include fostering innovation, maximizing patient access through pricing strategies, and maintaining agility to rapidly adapt to scientific and regulatory developments.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lung Cancer Therapeutics Market

The Lung Cancer Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increase in prevalence of lung cancer across the globe
  • Growing awareness regarding enhanced health care
  • Rising government initiatives for lung cancer treatment
• Market Restraints
  • Huge availability of the generic drugs
  • Reduced life expectancy of patients undertaking lung cancer treatment
• Market Opportunities
  • Increasing funding in the field of research and development of new treatment
  • Adoption of advanced therapy such as immunotherapy
• Market Challenges
  • Risk of side effects of radiation and chemotherapy

Porter's Five Forces: A Strategic Tool for Navigating the Lung Cancer Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lung Cancer Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lung Cancer Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lung Cancer Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lung Cancer Therapeutics Market

A detailed market share analysis in the Lung Cancer Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lung Cancer Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lung Cancer Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lung Cancer Therapeutics Market

A strategic analysis of the Lung Cancer Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lung Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis AG, Pfizer Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Lung Cancer Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Molecules, market is studied across Biologics and Small Molecules.
• Based on Disease, market is studied across NSCLC and SCLC.
• Based on Cancer Type, market is studied across Lung Carcinoid Tumor, Non-small Cell Lung Cancer, and Small Cell Lung Cancer.
• Based on Therapy, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy, and Targeted Therapy. The Immunotherapy is further studied across Atezolizumab, Durvalumab, Nivolumab, and Pembrolizumab. The Radiation Therapy is further studied across External Beam, Internal Beam, and Systemic. The Targeted Therapy is further studied across Bevacizumab, Dabrafenib/Trametinib, Erlotinib Hydrochloride, and Osimertinib.
• Based on Distribution, market is studied across Hospital Pharmacies, Online Phramacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in prevalence of lung cancer across the globe
    • 5.1.1.2. Growing awareness regarding enhanced health care
    • 5.1.1.3. Rising government initiatives for lung cancer treatment
  • 5.1.2. Restraints
    • 5.1.2.1. Huge availability of the generic drugs
    • 5.1.2.2. Reduced life expectancy of patients undertaking lung cancer treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing funding in the field of research and development of new treatment
    • 5.1.3.2. Adoption of advanced therapy such as immunotherapy
  • 5.1.4. Challenges
    • 5.1.4.1. Risk of side effects of radiation and chemotherapy
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Lung Cancer Therapeutics Market, by Molecules

• 6.1. Introduction
• 6.2. Biologics
• 6.3. Small Molecules

7. Lung Cancer Therapeutics Market, by Disease

• 7.1. Introduction
• 7.2. NSCLC
• 7.3. SCLC

8. Lung Cancer Therapeutics Market, by Cancer Type

• 8.1. Introduction
• 8.2. Lung Carcinoid Tumor
• 8.3. Non-small Cell Lung Cancer
• 8.4. Small Cell Lung Cancer

9. Lung Cancer Therapeutics Market, by Therapy

• 9.1. Introduction
• 9.2. Chemotherapy
• 9.3. Immunotherapy
  • 9.3.1. Atezolizumab
  • 9.3.2. Durvalumab
  • 9.3.3. Nivolumab
  • 9.3.4. Pembrolizumab
• 9.4. Radiation Therapy
  • 9.4.1. External Beam
  • 9.4.2. Internal Beam
  • 9.4.3. Systemic
• 9.5. Targeted Therapy
  • 9.5.1. Bevacizumab
  • 9.5.2. Dabrafenib/Trametinib
  • 9.5.3. Erlotinib Hydrochloride
  • 9.5.4. Osimertinib

10. Lung Cancer Therapeutics Market, by Distribution

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Phramacies
• 10.4. Retail Pharmacies

11. Americas Lung Cancer Therapeutics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Lung Cancer Therapeutics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Lung Cancer Therapeutics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Astellas Pharma Inc.
• 3. AstraZeneca PLC
• 4. Boehringer Ingelheim GmbH
• 5. Bristol Myers Squibb Company
• 6. Celgene Corporation
• 7. Eli Lilly and Company
• 8. F. Hoffmann-La Roche AG
• 9. Genentech, Inc.
• 10. GlaxoSmithKline PLC
• 11. Merck KGaA
• 12. Novartis AG
• 13. Pfizer Inc.
• 14. Sanofi S.A.